Skip to main content
OpenTrials
Completed

NCT Number: NCT03395223

MEthylene Blue In Patients With Acquired Methemoglobinemia

This is an open label, uncontrolled, Phase 4 study including 10 patients who present in hospital/urgent care setting with acquired methemoglobinemia. The population may include pediatric and adult patients (males and females of all ages are included).

The study will run in both the EU and the US. The aim of the study is to confirm safety and efficacy of ProvayBlueTM for the treatment of acquired methemoglobinemia and has been requested by the US-FDA as a Post-Marketing requirements.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acquired Methaemoglobinaemia

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hôpital Lariboisière

Paris, 75475, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pediatric or adult patients (males and females of all ages are included) diagnosed with acquired methemoglobinemia and receiving treatment with ProvayBlue™ as per the treating physician's diagnosis and hospital standard of care.

Acquired methemoglobinemia is defined as a level of methemoglobinemia >30% or ≤30% in case of clinical symptoms (e.g. sleepiness, cyanosis, dizziness, etc.).

  • Written informed consent obtained prior to any data collection (retrospective and prospective) for this study and study specific assessments.

Exclusion criteria

  • Known severe hypersensitivity reactions to methylene blue or any other thiazine dye;
  • Known deficiency in glucose-6-phosphate dehydrogenase (G6PD) due to the risk of hemolytic anemia as well as lack of therapeutic effect;
  • Known deficiency in Nicotinamide Adenine Dinucleotide Phosphate Hydrogen (NADPH) reductase.
  • Known use of selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), MonoAmine Oxidase (MAO) inhibitors or drugs metabolised via CYP isoenzymes anticipated during the treatment phase of the study.
  • Women who refuse to stop breastfeeding for up to 8 days after receiving the last dose of ProvayBlueTM.

Treatment and study plan

Methylene Blue

Drug

Administration of Methylene Blue to treat acquired methaemoglobinaemia

Other names: ProvayBlue

Primary outcomes

  1. Primary Efficacy Endpoint: Number of Participants With and Without 50% Reduction in metHb Level

    Time frame: 1 hour

    A 50% reduction in metHb level within 1 hour of the first dose of ProvayBlue for treatment of acquired methemoglobinemia. The timing of postdosing metHb level assays is inconsistent in clinical practice, for that reason metHb level at 1-hour postdosing was derived using linear interpolation.

Secondary outcomes

  1. Number of Participants With and Without Concomitant Normalization of Respiratory Rate

    Time frame: 2 hours

    Normalization of the respiratory rate within 2 hours of the first dose of ProvayBlue. The normal range used for respiratory rate was 12-20 breaths per minute.

  2. Number of Participants With and Without Concomitant Normalization of Heart Rate

    Time frame: 2 hours

    Normalization of the heart rate within 2 hours of the first dose of ProvayBlue. The normal range used for heart rate was 50-100 beats per minute.

  3. Number of Participants With and Without Concomitant Normalization of Blood Pressure

    Time frame: 2 hours

    Normalization of blood pressure standard values within 2 hours of the first dose of ProvayBlue. The normal range used for systolic blood pressure was was 90-140 mm HG and the normal range used for diastolic blood pressure was 60-90 mm HG.

  4. Second Dose

    Time frame: 1 hour

    Evaluation of the patients who achieve a 50% reduction in metHb level after a second dose of ProvayBlue

  5. Number of Participants With Treatment-related Adverse Events

    Time frame: 24 hours

    Number of participants who experience a treatment emergent adverse event assessed by the investigator as being related to study drug..

  6. Methylene Blue Content in Blood Samples

    Time frame: 24 hours

    Blood samples will be analyzed for methylene blue content

  7. Azure B Content in Blood Samples

    Time frame: 24 hours

    Blood samples will be analyzed for Azure B content

Sponsors and collaborators

Lead sponsor

Provepharm SAS

Industry

Registry information

Official study title

Open Label Clinical Study to Evaluate the Safety and Efficacy of ProvayBlueTM (Methylene Blue) for the Treatment of Acquired Methemoglobinemia

Acronym: MEBIPAM

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Jan 10, 2018
Registry last updated
Apr 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.